Paul Moorehead/LinkedIn
Aug 6, 2025, 10:47
Conquering Factor VIII Inhibitors: New Insights Into the ‘Devil’ of Hemophilia A Treatment Resistance
Flora Peyvandi posted on X:
”Exorcizing the devil of factor VIII inhibitors”
“For the Devil is a gentleman, and doesn’t keep his word” – G.K. Chesterton
In this issue of Blood Advances, Butera et al shed some light on the mystery of factor VIII (FVIII) inhibitors, the most diabolical complication of FVIII replacement therapy in patients with hemophilia A. Their work examined the impact of disulfide bonds on the antigenicity of the FVIII molecule, with possible implications for the understanding of immune responses to exogenous FVIII and for drug design.
Read the full article here.
Auothor: Paul C. Moorehead
Stay updated with Hemostasis Today.
-
Sep 7, 2026, 13:32Jason Fung: Why Genetic and Epidemiologic Data Cannot Fully Prove That Lp(a) Directly Causes Cardiovascular Disease
-
Sep 7, 2026, 13:23Pablo Demelo: A review on the Treatment of Recurrent ETV
-
Sep 7, 2026, 13:20Muhammad Ahsan: Advancing Evidence in Antithrombotic Therapy After STEMI
-
Sep 7, 2026, 13:13Flora Peyvandi: WES Identifies Key Genetic Variants Underlying Low vWF Levels
-
Sep 7, 2026, 12:00Sanjeev Bagai: How Platelet-Derived Serotonin Drives Lung Injury
-
Sep 7, 2026, 11:25Yoseph Samodra: Hematopoiesis and the Nutrients Behind Blood Formation
-
Sep 7, 2026, 09:31Felix Scholkmann: Serotonin and the Formation of Microvascular Fibrin
-
Sep 7, 2026, 09:22Aryan Mishra: β-Thalassemia Analyzer – HPLC for Hemoglobinopathy Screening
-
Sep 7, 2026, 09:04Daniel Pereira Monteiro: Haemopaedia Case of the Week – Hemoglobinopathy Diagnosis and Confirmatory Testing